Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 170030
  • calendar_today Published On: Mar, 2021
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Amyotrophic Lateral Sclerosis (ALS) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Amyotrophic Lateral Sclerosis (ALS) Treatment size is estimated to be USD 391.6 million in 2026 from USD 303.2 million in 2020, with a change XX% between 2020 and 2021. The global Amyotrophic Lateral Sclerosis (ALS) Treatment market size is expected to grow at a CAGR of 6.6% for the next five years.

Market segmentation

Amyotrophic Lateral Sclerosis (ALS) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Riluzole

Edaravone (Radicava)

Other

Market segment by Application, can be divided into

Hospital

Drugs Store

Other

Market segment by players, this report covers

Mitsubishi Tanabe Pharma

Sanofi

Mylan Pharma

Apotex

Glemark Generics

Covis Pharma

Sun Pharma

Lunan Pharma

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Amyotrophic Lateral Sclerosis (ALS) Treatment

1.2 Classification of Amyotrophic Lateral Sclerosis (ALS) Treatment by Type

1.2.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type in 2020

1.2.3 Riluzole

1.2.4 Edaravone (Radicava)

1.2.5 Other

1.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application

1.3.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hospital

1.3.3 Drugs Store

1.3.4 Other

1.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size & Forecast

1.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast by Region

1.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region, (2016-2021)

1.5.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2016-2026)

1.5.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2016-2026)

1.5.6 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers

1.6.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints

1.6.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Trends Analysis

2 Company Profiles

2.1 Mitsubishi Tanabe Pharma

2.1.1 Mitsubishi Tanabe Pharma Details

2.1.2 Mitsubishi Tanabe Pharma Major Business

2.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

2.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Mitsubishi Tanabe Pharma Recent Developments and Future Plans

2.2 Sanofi

2.2.1 Sanofi Details

2.2.2 Sanofi Major Business

2.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

2.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Sanofi Recent Developments and Future Plans

2.3 Mylan Pharma

2.3.1 Mylan Pharma Details

2.3.2 Mylan Pharma Major Business

2.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

2.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Mylan Pharma Recent Developments and Future Plans

2.4 Apotex

2.4.1 Apotex Details

2.4.2 Apotex Major Business

2.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

2.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Apotex Recent Developments and Future Plans

2.5 Glemark Generics

2.5.1 Glemark Generics Details

2.5.2 Glemark Generics Major Business

2.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

2.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Glemark Generics Recent Developments and Future Plans

2.6 Covis Pharma

2.6.1 Covis Pharma Details

2.6.2 Covis Pharma Major Business

2.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

2.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 Covis Pharma Recent Developments and Future Plans

2.7 Sun Pharma

2.7.1 Sun Pharma Details

2.7.2 Sun Pharma Major Business

2.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

2.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Sun Pharma Recent Developments and Future Plans

2.8 Lunan Pharma

2.8.1 Lunan Pharma Details

2.8.2 Lunan Pharma Major Business

2.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

2.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Lunan Pharma Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share

3.2.2 Top 10 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share

3.2.3 Market Competition Trend

3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Market Share by Type (2016-2021)

4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2016-2021)

5.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2016-2026)

6.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2026)

6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country

6.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2016-2026)

6.3.2 United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

6.3.3 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

6.3.4 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2016-2026)

7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2026)

7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country

7.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2016-2026)

7.3.2 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

7.3.3 France Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

7.3.5 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

7.3.6 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2016-2026)

8.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2026)

8.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region

8.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Region (2016-2026)

8.3.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

8.3.3 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

8.3.4 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

8.3.5 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

8.3.7 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2016-2026)

9.2 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2026)

9.3 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country

9.3.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2016-2026)

9.3.2 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

9.3.3 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2016-2026)

10.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2026)

10.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country

10.3.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2016-2026)

10.3.2 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

10.3.4 UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) by Region (2016-2021)

Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Region (2021-2026)

Table 6. Mitsubishi Tanabe Pharma Corporate Information, Head Office, and Major Competitors

Table 7. Mitsubishi Tanabe Pharma Major Business

Table 8. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

Table 9. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Sanofi Corporate Information, Head Office, and Major Competitors

Table 11. Sanofi Major Business

Table 12. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

Table 13. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Mylan Pharma Corporate Information, Head Office, and Major Competitors

Table 15. Mylan Pharma Major Business

Table 16. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

Table 17. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Apotex Corporate Information, Head Office, and Major Competitors

Table 19. Apotex Major Business

Table 20. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

Table 21. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Glemark Generics Corporate Information, Head Office, and Major Competitors

Table 23. Glemark Generics Major Business

Table 24. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

Table 25. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. Covis Pharma Corporate Information, Head Office, and Major Competitors

Table 27. Covis Pharma Major Business

Table 28. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

Table 29. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Sun Pharma Corporate Information, Head Office, and Major Competitors

Table 31. Sun Pharma Major Business

Table 32. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

Table 33. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Lunan Pharma Corporate Information, Head Office, and Major Competitors

Table 35. Lunan Pharma Major Business

Table 36. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions

Table 37. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) by Players (2019-2021)

Table 39. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Players (2019-2021)

Table 40. Breakdown of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)

Table 41. Amyotrophic Lateral Sclerosis (ALS) Treatment Players Head Office, Products and Services Provided

Table 42. Amyotrophic Lateral Sclerosis (ALS) Treatment Mergers & Acquisitions in the Past Five Years

Table 43. Amyotrophic Lateral Sclerosis (ALS) Treatment New Entrants and Expansion Plans

Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) by Type (2016-2021)

Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type (2016-2021)

Table 46. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Forecast by Type (2021-2026)

Table 47. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2021)

Table 48. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Forecast by Application (2021-2026)

Table 49. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2016-2021) & (USD Million)

Table 50. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (USD Million)

Table 51. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2021) & (USD Million)

Table 52. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (USD Million)

Table 53. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2016-2021) & (USD Million)

Table 54. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026) & (USD Million)

Table 55. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2016-2021) & (USD Million)

Table 56. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (USD Million)

Table 57. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2021) & (USD Million)

Table 58. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (USD Million)

Table 59. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2016-2021) & (USD Million)

Table 60. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026) & (USD Million)

Table 61. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2016-2021) & (USD Million)

Table 62. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (USD Million)

Table 63. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2021) & (USD Million)

Table 64. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (USD Million)

Table 65. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Region (2016-2021) & (USD Million)

Table 66. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Region (2021-2026) & (USD Million)

Table 67. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2016-2021) & (USD Million)

Table 68. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (USD Million)

Table 69. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2021) & (USD Million)

Table 70. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (USD Million)

Table 71. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2016-2021) & (USD Million)

Table 72. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026) & (USD Million)

Table 73. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2016-2021) & (USD Million)

Table 74. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Type (2021-2026) & (USD Million)

Table 75. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2016-2021) & (USD Million)

Table 76. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Application (2021-2026) & (USD Million)

Table 77. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2016-2021) & (USD Million)

Table 78. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Amyotrophic Lateral Sclerosis (ALS) Treatment Picture

Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type in 2020

Figure 3. Riluzole

Figure 4. Edaravone (Radicava)

Figure 5. Other

Figure 6. Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application in 2020

Figure 7. Hospital Picture

Figure 8. Drugs Store Picture

Figure 9. Other Picture

Figure 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 11. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Forecast (2016-2026) & (USD Million)

Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Region (2016-2026)

Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Region in 2020

Figure 14. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 15. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 16. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers

Figure 20. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints

Figure 21. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends

Figure 22. Mitsubishi Tanabe Pharma Recent Developments and Future Plans

Figure 23. Sanofi Recent Developments and Future Plans

Figure 24. Mylan Pharma Recent Developments and Future Plans

Figure 25. Apotex Recent Developments and Future Plans

Figure 26. Glemark Generics Recent Developments and Future Plans

Figure 27. Covis Pharma Recent Developments and Future Plans

Figure 28. Sun Pharma Recent Developments and Future Plans

Figure 29. Lunan Pharma Recent Developments and Future Plans

Figure 30. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Players in 2020

Figure 31. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 32. Global Top 3 Players Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share in 2020

Figure 33. Global Top 10 Players Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share in 2020

Figure 34. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 35. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Type in 2020

Figure 36. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Type (2021-2026)

Figure 37. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Share by Application in 2020

Figure 38. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Application (2021-2026)

Figure 39. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Market Share by Type (2016-2026)

Figure 40. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Market Share by Application (2016-2026)

Figure 41. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Country (2016-2026)

Figure 42. United States Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 43. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 44. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 45. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Market Share by Type (2016-2026)

Figure 46. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Market Share by Application (2016-2026)

Figure 47. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Country (2016-2026)

Figure 48. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 49. France Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 50. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 51. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 52. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Market Share by Type (2016-2026)

Figure 54. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Market Share by Application (2016-2026)

Figure 55. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Region (2016-2026)

Figure 56. China Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 57. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 58. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 59. India Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 60. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Market Share by Type (2016-2026)

Figure 63. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Market Share by Application (2016-2026)

Figure 64. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Country (2016-2026)

Figure 65. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 66. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 67. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Market Share by Type (2016-2026)

Figure 68. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Sales Market Share by Application (2016-2026)

Figure 69. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Country (2016-2026)

Figure 70. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 72. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. Methodology

Figure 74. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz